サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405963

低分子CDMOの市場規模、シェア、動向分析レポート：製品別、薬剤タイプ別、用途別、地域別、セグメント別予測、2024年～2030年

Small Molecule CDMO Market Size, Share & Trends Analysis Report By Drug Type (Generics, Innovators), By Product (APIs, Finished Drug Products), By Application (Oncology, CVD, CNS Conditions), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
低分子CDMOの市場規模、シェア、動向分析レポート：製品別、薬剤タイプ別、用途別、地域別、セグメント別予測、2024年～2030年
出版日: 2023年12月11日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

低分子CDMO市場の成長と動向：

Grand View Research, Inc.の新しい調査によると、世界の低分子CDMO市場規模は2024年から2030年にかけて7.1%のCAGRを記録し、2030年には1,084億6,000万米ドルに達すると予測されています。

低分子医薬品開発における革新的技術の開発、低分子治療薬に焦点を当てた医薬品パイプラインの拡大、費用対効果が高く専門的な製造サービスを提供するCDMO（医薬品開発製造受託機関）への依存の高まり、効率的な医薬品開発・製造プロセスを支援する規制の枠組み、業界の需要に応えるために製造能力を拡大するCDMOなどは、市場成長を支える要因の一部です。製薬企業にとって、技術革新と診療所への容易なアクセスは重要な要素です。

小規模企業や特殊製薬企業は、業界内でこれらの重要な要件を提供することにますます依存するようになっています。CDMOの多くは、ワンストップショップ企業としての地位を確立しています。ワンストップショップ・サービスモデルとは、CDMOが原薬（API）から剤形、初期開発から商業化まですべてを提供するものです。このようなサービスを提供するためには、CDMOは特定の問題記述に対応するための幅広い実現技術や専門的な処理能力を有していなければならないです。研究、開発、製造の全サービスを提供するCDMOが世界中に相当数存在することが、市場の成長を支えるものと予想されます。慢性疾患の有病率の高さも、新規の低分子ベースの治療薬の開発を支える大きな要因であり、CDMOサービスの需要を押し上げています。

国際糖尿病連合（IDF）は、糖尿病の罹患率が国内で徐々に上昇していると述べています。それによると、2022年には中国で1億4,000万人以上が糖尿病に罹患し、2030年には1億7,440万人が糖尿病と診断される見込みです。不健康な脂肪の大量消費と座りっぱなしのライフスタイルが、糖尿病発症率を高めている主な要因です。糖尿病の負担の増大は、同国におけるCDMOサービスの需要を促進すると予想されます。医薬品研究開発への多額の投資は、業界の成長を後押しする重要な原動力です。製薬会社が低分子治療薬の発見・開発に力を入れるにつれ、CDMOサービスに対する需要も増加しています。これらのサービスは、低分子医薬品の効率的かつ費用対効果の高い開発・製造において極めて重要です。

低分子CDMO市場レポートハイライト

  • 新薬開発のための研究開発イニシアチブの増加により、2023年にはAPIセグメントが62.3%の最大シェアを占めました。また、大手製薬企業の強固な医薬品パイプラインも同分野の成長を後押ししています。
  • ジェネリック医薬品セグメントは、2024年から2030年までのCAGRが8.0%と最も高くなると予測されます。がん、糖尿病、心血管疾患（CVD）などの疾病負担の高さ、ジェネリック医薬品へのアクセスを改善するための各国政府の取り組みが、同分野の成長に寄与する主な要因です。
  • がん領域は、世界のがん患者数の増加により、2023年には35.1%と最も高い売上シェアを占めました。さらに、政府の償還政策が強化され、低分子のがん治療薬開発への資金調達が増加していることも、同分野の成長を後押しすると予想されます。
  • アジア太平洋地域は、2024年から2030年までのCAGRが7.7%と最も高くなると予想されています。北米や欧州に比べて製造コストが格段に安く、法律も整備されているため、アジア太平洋、特に中国とインドが圧倒的な地域市場を維持しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 低分子CDMO市場変数、動向および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 低分子CDMO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 低分子CDMO市場：製品の推定・動向分析

  • 定義と範囲
  • 製品の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 製品別の世界の低分子CDMO市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで
    • 医薬品有効成分（API）
    • 医薬品完成品

第5章 低分子CDMO市場：薬剤タイプの推定・動向分析

  • 定義と範囲
  • 薬剤タイプの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 薬剤タイプ別の世界の低分子CDMO市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで
    • イノベーター
    • ジェネリック

第6章 低分子CDMO市場：用途の推定・動向分析

  • 定義と範囲
  • 用途の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 用途別の世界の低分子CDMO市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで
    • 腫瘍
    • 循環器疾患
    • 中枢神経系（CNS）疾患
    • 自己免疫/炎症
    • その他

第7章 低分子CDMO市場：地域の推定・動向分析

  • 地域の市場シェア分析、2023年および2030年
  • 地域の市場ダッシュボード
  • 世界の地域の市場スナップショット
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • インド
    • 中国
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 市場参入企業の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレイヤー
    • 企業の市場シェア分析、2023年
  • 企業プロファイル
    • Lonza
    • Catalent, Inc
    • Thermo Fisher Scientific Inc.
    • Cambrex Corporation
    • Bellen Chemistry
    • Siegfried Holding AG
    • Recipharm AB
    • Eurofins Scientific
    • Aurigene Pharmaceutical Services Ltd.
    • CordenPharma International
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 5 North America Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 7 U.S. Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 10 Canada Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Europe Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 15 Europe Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 17 Germany Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Germany Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 20 UK Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 21 UK Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 22 France Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 23 France Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 France Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Italy Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 27 Italy Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 30 Spain Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 32 Denmark Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 35 Sweden Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Norway Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 39 Norway Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 44 China Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 45 China Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 46 China Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Japan Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 50 India Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 51 India Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 52 India Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 54 South Korea Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 57 Australia Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 58 Australia Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Thailand Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 63 Latin America Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 65 Brazil Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Brazil Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 68 Mexico Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 69 Mexico Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 71 Argentina Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 72 Argentina Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 74 MEA Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 76 MEA Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 77 MEA Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 78 South Africa Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 79 South Africa Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 84 UAE Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 85 UAE Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 86 UAE Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 87 Kuwait Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 QFD modeling for market share assessment
  • Fig. 11 Market formulation & validation
  • Fig. 12 Small Molecule CDMO market: market outlook
  • Fig. 13 Small Molecule CDMO competitive insights
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Industry value chain analysis
  • Fig. 17 Small Molecule CDMO market driver impact
  • Fig. 18 Small Molecule CDMO market restraint impact
  • Fig. 19 Small Molecule CDMO market: Product movement analysis
  • Fig. 20 Small Molecule CDMO market: Product outlook and key takeaways
  • Fig. 21 Active Pharmaceutical Ingredients (API) market estimates and forecast, 2018 - 2030
  • Fig. 22 Finished Drug Products estimates and forecast, 2018 - 2030
  • Fig. 23 Small Molecule CDMO Market: Drug Type Movement Analysis
  • Fig. 24 Small Molecule CDMO market: Drug Type outlook and key takeaways
  • Fig. 25 Innovators market estimates and forecast, 2018 - 2030
  • Fig. 26 Generics market estimates and forecast, 2018 - 2030
  • Fig. 27 Small Molecule CDMO market: application movement analysis
  • Fig. 28 Small Molecule CDMO market: application outlook and key takeaways
  • Fig. 29 Oncology market estimates and forecast, 2018 - 2030
  • Fig. 30 Cardiovascular Disease market estimates and forecast, 2018 - 2030
  • Fig. 31 Central Nervous System (CNS) Conditions market estimates and forecast, 2018 - 2030
  • Fig. 32 Autoimmune/Inflammation market estimates and forecast, 2018 - 2030
  • Fig. 33 Other market estimates and forecast, 2018 - 2030
  • Fig. 34 Global Small Molecule CDMO market: Regional movement analysis
  • Fig. 35 Global Small Molecule CDMO market: Regional outlook and key takeaways
  • Fig. 36 North America
  • Fig. 37 North America market estimates and forecast, 2018 - 2030
  • Fig. 38 U.S.
  • Fig. 39 U.S. market estimates and forecast, 2018 - 2030
  • Fig. 40 Canada
  • Fig. 41 Canada market estimates and forecast, 2018 - 2030
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2018 - 2030
  • Fig. 44 UK
  • Fig. 45 UK market estimates and forecast, 2018 - 2030
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2018 - 2030
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2018 - 2030
  • Fig. 50 Italy
  • Fig. 51 Italy market estimates and forecast, 2018 - 2030
  • Fig. 52 Spain
  • Fig. 53 Spain market estimates and forecast, 2018 - 2030
  • Fig. 54 Denmark
  • Fig. 55 Denmark market estimates and forecast, 2018 - 2030
  • Fig. 56 Sweden
  • Fig. 57 Sweden market estimates and forecast, 2018 - 2030
  • Fig. 58 Norway
  • Fig. 59 Norway market estimates and forecast, 2018 - 2030
  • Fig. 60 Asia Pacific
  • Fig. 61 Asia Pacific market estimates and forecast, 2018 - 2030
  • Fig. 62 China
  • Fig. 63 China market estimates and forecast, 2018 - 2030
  • Fig. 64 Japan
  • Fig. 65 Japan market estimates and forecast, 2018 - 2030
  • Fig. 66 India
  • Fig. 67 India market estimates and forecast, 2018 - 2030
  • Fig. 68 Thailand
  • Fig. 69 Thailand market estimates and forecast, 2018 - 2030
  • Fig. 70 South Korea
  • Fig. 71 South Korea market estimates and forecast, 2018 - 2030
  • Fig. 72 Australia
  • Fig. 73 Australia market estimates and forecast, 2018 - 2030
  • Fig. 74 Latin America
  • Fig. 75 Latin America market estimates and forecast, 2018 - 2030
  • Fig. 76 Brazil
  • Fig. 77 Brazil market estimates and forecast, 2018 - 2030
  • Fig. 78 Mexico
  • Fig. 79 Mexico market estimates and forecast, 2018 - 2030
  • Fig. 80 Argentina
  • Fig. 81 Argentina market estimates and forecast, 2018 - 2030
  • Fig. 82 Middle East and Africa
  • Fig. 83 Middle East and Africa market estimates and forecast, 2018 - 2030
  • Fig. 84 South Africa
  • Fig. 85 South Africa market estimates and forecast, 2018 - 2030
  • Fig. 86 Saudi Arabia
  • Fig. 87 Saudi Arabia market estimates and forecast, 2018 - 2030
  • Fig. 88 UAE
  • Fig. 89 UAE market estimates and forecast, 2018 - 2030
  • Fig. 90 Kuwait
  • Fig. 91 Kuwait market estimates and forecast, 2018 - 2030
  • Fig. 92 Market share of key market players - Small Molecule CDMO market
目次
Product Code: GVR-4-68040-165-6

Small Molecule CDMO Market Growth & Trends:

The global small molecule CDMO market size is expected to reach USD 108.46 billion by 2030, registering a CAGR of 7.1% from 2024 to 2030, according to a new study by Grand View Research, Inc. Exploration of innovative technologies in small molecule drug development, expansion of pharmaceutical pipelines with a focus on small molecule therapeutics, growing reliance on contract development and manufacturing organizations (CDMOs) for cost-effective and specialized manufacturing services, regulatory frameworks supporting efficient drug development & manufacturing processes, and CDMOs expanding manufacturing capacities to meet industry demands are few of the factors supporting market growth. For pharmaceutical companies, innovation and easy access to clinics are critical factors.

Small-scale companies and specialty pharmaceutical players increasingly rely on delivering these important requirements within the industry. Many CDMOs establish themselves as one-stop-shop companies. The one-stop-shop service model is where a CDMO offers everything, from active pharmaceutical ingredient (API) to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities that help address specific problem statements. A significant number of CDMOs across the globe providing all research, development, and manufacturing services is expected to support market growth. The high prevalence of chronic ailments is another considerable factor supporting the development of novel small molecule-based therapeutics, thus boosting CDMO services demand.

The International Diabetes Federation (IDF) states that the incidence of diabetes is rising gradually in the country. It states that in 2022, over 140 million people in China had diabetes, and 174.4 million are expected to be diagnosed by 2030. High consumption of unhealthy fats and a sedentary lifestyle are major factors contributing to the high incidence of diabetes. The growing burden of diabetes is expected to drive CDMO services demand in the country. Substantial investment in pharmaceutical R&D is a significant driver bolstering industry growth. As pharmaceutical companies intensify their efforts in discovering & developing small molecule therapeutics, there is a corresponding rise in demand for CDMO services. These services are crucial in the efficient & cost-effective development & manufacturing of small-molecule drugs.

Small Molecule CDMO Market Report Highlights:

  • The API segment accounted for the largest share of 62.3% in 2023 due to increased R&D initiatives for novel medicine development. The robust drug pipelines of major pharmaceutical players also propel segment growth
  • The generics drug type segment is anticipated to have the highest CAGR of 8.0% from 2024 to 2030. The high burden of diseases, such as cancer, diabetes, and cardiovascular disorders (CVDs), and initiatives by the governments to improve access to generic drugs are the key factors contributing to segment growth
  • The oncology segment held the highest revenue share of 35.1% in 2023 owing to an increasing number of cancer cases globally. Furthermore, increased government reimbursement policies and a rise in financing for developing small molecule oncology therapies are expected to boost segment growth
  • Asia Pacific is anticipated to witness the highest CAGR of 7.7% from 2024 to 2030. Due to significantly cheaper manufacturing costs than North America & Europe and favorable laws, Asia Pacific, particularly China & India, has remained the dominant regional market

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Drug Type
    • 1.1.3. Application
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Parent Market Analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Drug Type outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Small Molecule CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rise in drug development pipelines
      • 3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
      • 3.2.1.3. Capacity expansions by CDMOS
      • 3.2.1.4. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Growing demand for biologics
      • 3.2.2.2. Complexity and challenges in synthesis of certain small molecules, impacting manufacturing efficiency
  • 3.3. Small Molecule CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Active Pharmaceutical Ingredients (API)
    • 4.1.2. Finished Drug Products
  • 4.2. Product Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Small Molecule CDMO Market by Product Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Active Pharmaceutical Ingredients (APIs)
      • 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Finished Drug Products
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Innovators
    • 5.1.2. Generics
  • 5.2. Drug Type Market Share, 2023 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Global Small Molecule CDMO Market by Drug Type Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Innovators
      • 5.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2. Generics
      • 5.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
    • 6.1.2. Cardiovascular Disease
    • 6.1.3. Central Nervous System (CNS) Conditions
    • 6.1.4. Autoimmune/Inflammation
    • 6.1.5. Others
  • 6.2. Application Market Share, 2023 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Global Small Molecule CDMO Market by Application Outlook
  • 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.5.1. Oncology
      • 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.2. Cardiovascular Disease
      • 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.3. Central Nervous System (CNS) Conditions
      • 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.4. Autoimmune/Inflammation
      • 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.5. Others
      • 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Lonza
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Catalent, Inc
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Thermo Fisher Scientific Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Cambrex Corporation
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Bellen Chemistry
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Siegfried Holding AG
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Recipharm AB
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Eurofins Scientific
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Aurigene Pharmaceutical Services Ltd.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. CordenPharma International
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Service benchmarking
      • 8.2.10.4. Strategic initiatives